- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.01. | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 31.12.24 | RACE ONCOLOGY LTD: Appendix 3X - Dr Megan Baldwin | - | ASX | ||
| 26.12.24 | Biocurious: Behind Race Oncology's quest to prevent chemo from being worse than the disease | 2 | Stockhead | ||
| RACE ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.12.24 | Race Oncology bolsters leadership with key appointment | 1 | Stockhead | ||
| 17.12.24 | RACE ONCOLOGY LTD: Race Receives $5.25m RD Tax Refund for Financial Year 2024 | 1 | ASX | ||
| 16.12.24 | RACE ONCOLOGY LTD: Race Strengthens Board | - | ASX | ||
| 03.12.24 | RACE ONCOLOGY LTD: Race Submits Human Ethics for RC220 Phase 1 Trial | - | ASX | ||
| 28.11.24 | RACE ONCOLOGY LTD: Race 2024 Annual General Meeting Video Release | 1 | ASX | ||
| 26.11.24 | RACE ONCOLOGY LTD: Appendix 3Y - Dr Serge Scrofani | 1 | ASX | ||
| 26.11.24 | RACE ONCOLOGY LTD: Notification regarding unquoted securities - RAC | - | ASX | ||
| 25.11.24 | RACE ONCOLOGY LTD: Results of Annual General Meeting | 1 | ASX | ||
| 24.11.24 | RACE ONCOLOGY LTD: Race Oncology 2024 Chairs Address and AGM Presentation | - | ASX | ||
| 24.11.24 | Long Shortz with Race Oncology: collaboration with Monash University | 1 | Stockhead | ||
| 22.11.24 | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 21.11.24 | Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today | 3 | The Motley Fool Australia | ||
| 19.11.24 | RACE ONCOLOGY LTD: Race Discovers Multiple Novel FTO Inhibitor Candidates | - | ASX | ||
| 07.11.24 | RACE ONCOLOGY LTD: Notification regarding unquoted securities - RAC | 1 | ASX | ||
| 23.10.24 | RACE ONCOLOGY LTD: Annual Report to Shareholders | 3 | ASX | ||
| 23.10.24 | RACE ONCOLOGY LTD: Letter to Shareholders, Notice of AGM & Proxy Form | 1 | ASX | ||
| 21.10.24 | Race Oncology concludes successful Phase 1b/2 trial, secures R&D tax incentive | 2 | Finance News Network |
Seite:
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 50,48 | 0,00 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,490 | 0,00 % | Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday | ||
| SUMMIT THERAPEUTICS | 23,500 | 0,00 % | Why Summit Therapeutics Stock Is Jumping Today | ||
| SANA BIOTECHNOLOGY | 3,500 | 0,00 % | Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5% - Here's Why | ||
| ABSCI | 4,025 | 0,00 % | Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside | ||
| METAGENOMI | 3,020 | 0,00 % | Metagenomi, Inc.: Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones | MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing... ► Artikel lesen | |
| QIAGEN | 45,430 | -1,31 % | Qiagen zahlt Ende Januar 1,26 US-Dollar je Aktie aus | VENLO (dpa-AFX) - Der Diagnostikspezialist und Labordienstleister Qiagen hat Details zu seinem sogenannten synthetischen Aktienrückkauf in Höhe von rund 300 Millionen US-Dollar bekanntgegeben. Je 36... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,530 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| JANUX THERAPEUTICS | 40,250 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 30,020 | -2,66 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| QUANTUM-SI | 2,380 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| ARCELLX | 65,87 | -1,05 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| NUVALENT | 81,33 | 0,00 % | Nuvalent-CEO Porter James Richard verkauft Aktien im Wert von 2,05 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 35,025 | 0,00 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,110 | 0,00 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen |
Das Unternehmen RACE ONCOLOGY LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,775 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACE ONCOLOGY LTD finden Sie auf Wallstreet Online.
